Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. The deficiency of immunoglobulin requires the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIg is manufactured from human plasma. It contains antibodies and is used in the treatment of a growing number of immunologic, haematologic and neurologic illnesses.
Takeda Pharmaceutical Company Limited and Grifols, S.A. – Notable Market Players in Intravenous Immunoglobulin Market
The intravenous immunoglobulin market majorly consists of the players such as Takeda Pharmaceutical Company Limited, Grifols, S.A., Pfizer Inc., ADMA Biologics Inc., Bio Products Laboratory Ltd., Shanghai RAAS, Octapharma AG, Kedrion S.p.A, CSL Behring (CSL Limited), and Prothya Biosolutions B.V. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the intravenous immunoglobulin market:
| Year | News |
| Aug-2021 | The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded seven years of marketing exclusivity for Octapharma’s Octagam 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis (DM). This approval will exclusively drive the growth of Octagam sales. |
| Jun-2021 | Octapharma announced that octagam 10%, a human plasma-derived intravenous immunoglobulin (IVIg), has recently been granted approval in the European Union (EU) as an immunomodulatory therapy for adults with dermatomyositis. Following the EU approval, octagam 10% received national approval in Germany on May 11, 2021, with approval in other European member states expected soon. |
| Apr-2021 | The U.S. Food and Drug Administration (“FDA”) has granted approval for the Company’s expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin (“IVIg”). |
| Jul-2021 | Prothya Biosolutions was formed by the merger of Plasma Industries Belgium with Sanquin Blood Supply Foundation. Plasma Industries Belgium (PIBe), with roots in the Belgian Red Cross, integrated with Sanquin Plasma Products (SPP), a former subsidiary of the Sanquin Blood Supply Foundation (Stichting Sanquin Bloedvoorziening). |
| Apr-2021 | Bio Products Laboratory Ltd. and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL’s preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company’s global new product development programs. The agreement builds on BPL and ARG’s previous successful collaboration on clinical trial programs. |
